This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Brammer Bio, LLC
Brammer Bio, LLC, a leading player in the biopharmaceutical industry, is headquartered in the United States, with significant operational regions across North America and Europe. Founded in 2018, the company has quickly established itself as a trusted partner in the development and manufacturing of advanced therapies, particularly in the field of gene and cell therapy. Brammer Bio offers a unique suite of services, including viral vector manufacturing and process development, tailored to meet the specific needs of its clients. The company’s commitment to quality and innovation has positioned it as a key contributor to the rapidly evolving landscape of biotherapeutics. With a focus on accelerating the delivery of life-changing therapies, Brammer Bio continues to achieve notable milestones, solidifying its reputation as a leader in the contract development and manufacturing organisation (CDMO) sector.
DitchCarbon Score
How does Brammer Bio, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Brammer Bio, LLC's score of 66 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Brammer Bio, LLC, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Thermo Fisher Scientific Inc., which influences its climate commitments and emissions reporting. As part of its corporate family, Brammer Bio inherits climate initiatives and targets from Thermo Fisher Scientific Inc. This includes commitments to the Science Based Targets initiative (SBTi) and other sustainability frameworks. However, specific reduction targets or achievements for Brammer Bio itself have not been disclosed. Brammer Bio's climate strategy is aligned with its parent company's broader sustainability goals, which focus on reducing greenhouse gas emissions across all scopes. The absence of direct emissions data suggests that the company is in the process of developing its own specific targets and initiatives, potentially cascading from Thermo Fisher's established practices. In summary, while Brammer Bio, LLC does not currently report specific emissions figures, it is positioned within a corporate structure that prioritises climate action and sustainability, guided by the initiatives of Thermo Fisher Scientific Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Brammer Bio, LLC is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
